Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors
Matteo Santoni, Francesco Massari, Sergio Bracarda, Enrique Grande, Marc Matrana, Mimma Rizzo, Ugo De Giorgi, Umberto Basso, Gaetano Aurilio, Lorena Incorvaia, Angelo Martignetti, Javier Molina‐Cerrillo, Veronica Mollica, Alessandro Rizzo, Nicola Battelli
Topics & Concepts
MedicineCabozantinibAxitinibNivolumabRefractory (planetary science)IpilimumabInternal medicinePazopanibPembrolizumabOncologyRenal cell carcinomaSunitinibUrologyCancerImmunotherapyPhysicsAstrobiologyRenal cell carcinoma treatmentCancer Immunotherapy and BiomarkersFerroptosis and cancer prognosis